In silico modeling predicts drug sensitivity of patient-derived cancer cells

Journal of Translational Medicine

Volumn 12, Issue 1, 2014, Pages

  Pingle, Sandeep C ^a   Sultana, Zeba ^b   Pastorino, Sandra ^a   Jiang, Pengfei ^a   Mukthavaram, Rajesh ^a   Chao, Ying ^a   Bharati, Ila S ^a   Nomura, Natsuko ^a   Makale, Milan ^a   Abbasi, Taher ^c   Kapoor, Shweta ^b   Kumar, Ansu ^b   Usmani, Shahabuddin ^b   Agrawal, Ashish ^b   Vali, Shireen ^b,c   Kesari, Santosh ^a,d  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b Cairn India Ltd   (India)

^c CELLWORKS GROUP INC   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cancer; Deterministic model; Glioblastoma; In Silico modeling; Personalized therapy; Targeted therapy; Tumor profiling; Virtual tumor technology

Indexed keywords

B RAF KINASE; BORTEZOMIB; LAPATINIB; PALBOCICLIB; PROTEIN TYROSINE KINASE INHIBITOR; SELUMETINIB; ANTINEOPLASTIC AGENT;

ACCURACY; ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; COMPUTER MODEL; COMPUTER SIMULATION; DRUG TARGETING; GENE MUTATION; GENETIC ASSOCIATION; GLIOBLASTOMA; PREDICTION; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; VALIDATION PROCESS; DRUG SCREENING; HUMAN; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; COMPUTER SIMULATION; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; RETROSPECTIVE STUDIES;

EID: 84901239468     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-12-128     Document Type: Article

References (33)

1. Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med 2008, 359:492-507. 10.1056/NEJMra0708126, 18669428.
2. Mischel PS, Shai R, Shi T, Horvath S, Lu KV, Choe G, Seligson D, Kremen TJ, Palotie A, Liau LM, Cloughesy TF, Nelson SF. Identification of molecular subtypes of glioblastoma by gene expression profiling. Oncogene 2003, 22:2361-2373. 10.1038/sj.onc.1206344, 12700671.
3. TCGA Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008, 455:1061-1068. 10.1038/nature07385, 2671642, 18772890, TCGA.
4. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, Alexe G, Lawrence M, O'Kelly M, Tamayo P, Weir BA, Gabriel S, Winckler W, Gupta S, Jakkula L, Feiler HS, Hodgson JG, James CD, Sarkaria JN, Brennan C, Kahn A, Spellman PT, Wilson RK, Speed TP, Gray JW, Meyerson M, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010, 17:98-110. 10.1016/j.ccr.2009.12.020, 2818769, 20129251.
5. Deisboeck TS. Personalizing medicine: a systems biology perspective. Mol Syst Biol 2009, 5:249. 2671924, 19293829.
6. Deisboeck TS, Zhang L, Yoon J, Costa J. In silico cancer modeling: is it ready for prime time?. Nat Clin Pract Oncol 2009, 6:34-42. 10.1038/ncponc1237, 3212937, 18852721.
7. Woodward DE, Cook J, Tracqui P, Cruywagen GC, Murray JD, Alvord EC. A mathematical model of glioma growth: the effect of extent of surgical resection. Cell Prolif 1996, 29:269-288. 10.1111/j.1365-2184.1996.tb01580.x, 8809120.
8. Tracqui P, Cruywagen GC, Woodward DE, Bartoo GT, Murray JD, Alvord EC. A mathematical model of glioma growth: the effect of chemotherapy on spatio-temporal growth. Cell Prolif 1995, 28:17-31. 10.1111/j.1365-2184.1995.tb00036.x, 7833383.
9. Zhang L, Wang Z, Sagotsky JA, Deisboeck TS. Multiscale agent-based cancer modeling. J Math Biol 2009, 58:545-559. 10.1007/s00285-008-0211-1, 18787828.
10. Deisboeck TS, Wang Z, Macklin P, Cristini V. Multiscale cancer modeling. Annu Rev Biomed Eng 2011, 13:127-155. 10.1146/annurev-bioeng-071910-124729, 3883359, 21529163.
11. Almine JF, Wise SG, Hiob M, Singh NK, Tiwari KK, Vali S, Abbasi T, Weiss AS. Elastin sequences trigger transient proinflammatory responses by human dermal fibroblasts. FASEB J 2013, 27:3455-3465. 10.1096/fj.13-231787, 23671273.
12. Barve A, Gupta A, Solapure SM, Kumar A, Ramachandran V, Seshadri K, Vali S, Datta S. A kinetic platform for in silico modeling of the metabolic dynamics in Escherichia coli. Adv Appl Bioinform Chem 2010, 3:97-110. 3170011, 21918631.
13. Cirstea D, Hideshima T, Rodig S, Santo L, Pozzi S, Vallet S, Ikeda H, Perrone G, Gorgun G, Patel K, Desai N, Sportelli P, Kapoor S, Vali S, Mukherjee S, Munshi NC, Anderson KC, Raje N. Dual inhibition of akt/mammalian target of rapamycin pathway by nanoparticle albumin-bound-rapamycin and perifosine induces antitumor activity in multiple myeloma. Mol Cancer Ther 2010, 9:963-975. 10.1158/1535-7163.MCT-09-0763, 3096071, 20371718.
14. Equils O, Nambiar P, Hobel CJ, Smith R, Simmons CF, Vali S. A computer simulation of progesterone and Cox2 inhibitor treatment for preterm labor. PLoS One 2010, 5:e8502. 10.1371/journal.pone.0008502, 2811723, 20111699.
15. Harvey LE, Kohlgraf KG, Mehalick LA, Raina M, Recker EN, Radhakrishnan S, Prasad SA, Vidva R, Progulske-Fox A, Cavanaugh JE, Vali S, Brogden KA. Defensin DEFB103 bidirectionally regulates chemokine and cytokine responses to a pro-inflammatory stimulus. Sci Rep 2013, 3:1232. 3565171, 23390582.
16. Kannaiyan R, Hay HS, Rajendran P, Li F, Shanmugam MK, Vali S, Abbasi T, Kapoor S, Sharma A, Kumar AP, Chng WJ, Sethi G. Celastrol inhibits proliferation and induces chemosensitization through down-regulation of NF-kappaB and STAT3 regulated gene products in multiple myeloma cells. Br J Pharmacol 2011, 164:1506-1521. 10.1111/j.1476-5381.2011.01449.x, 3221104, 21506956.
17. Kaushik P, Gorin F, Vali S. Dynamics of tyrosine hydroxylase mediated regulation of dopamine synthesis. J Comput Neurosci 2007, 22:147-160. 10.1007/s10827-006-0004-8, 17053993.
18. Tandon R, Kapoor S, Vali S, Senthil V, Nithya D, Venkataramanan R, Sharma A, Talwadkar A, Ray A, Bhatnagar PK, Dastidar SG. Dual epidermal growth factor receptor (EGFR)/insulin-like growth factor-1 receptor (IGF-1R) inhibitor: a novel approach for overcoming resistance in anticancer treatment. Eur J Pharmacol 2011, 667:56-65. 10.1016/j.ejphar.2011.04.066, 21640718.
19. Vali S, Mythri RB, Jagatha B, Padiadpu J, Ramanujan KS, Andersen JK, Gorin F, Bharath MM. Integrating glutathione metabolism and mitochondrial dysfunction with implications for Parkinson's disease: a dynamic model. Neuroscience 2007, 149:917-930. 10.1016/j.neuroscience.2007.08.028, 17936517.
20. Vali S, Pallavi R, Kapoor S, Tatu U. Virtual prototyping study shows increased ATPase activity of Hsp90 to be the key determinant of cancer phenotype. Syst Synth Biol 2010, 4:25-33. 10.1007/s11693-009-9046-3, 2816227,2816227, 19856130.
21. Galli R, Binda E, Orfanelli U, Cipelletti B, Gritti A, De Vitis S, Fiocco R, Foroni C, Dimeco F, Vescovi A. Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res 2004, 64:7011-7021. 10.1158/0008-5472.CAN-04-1364, 15466194.
22. Lee J, Kotliarova S, Kotliarov Y, Li A, Su Q, Donin NM, Pastorino S, Purow BW, Christopher N, Zhang W, Park JK, Fine HA. Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell 2006, 9:391-403. 10.1016/j.ccr.2006.03.030, 16697959.
23. Garnett MJ, Edelman EJ, Heidorn SJ, Greenman CD, Dastur A, Lau KW, Greninger P, Thompson IR, Luo X, Soares J, Liu Q, Iorio F, Surdez D, Chen L, Milano RJ, Bignell GR, Tam AT, Davies H, Stevenson JA, Barthorpe S, Lutz SR, Kogera F, Lawrence K, McLaren-Douglas A, Mitropoulos X, Mironenko T, Thi H, Richardson L, Zhou W, Jewitt F, et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 2012, 483:570-575. 10.1038/nature11005, 3349233, 22460902.
24. Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, Kutzner H, Cho KH, Aiba S, Brocker EB, LeBoit PE, Pinkel D, Bastian BC. Distinct sets of genetic alterations in melanoma. N Engl J Med 2005, 353:2135-2147. 10.1056/NEJMoa050092, 16291983.
25. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, et al. Mutations of the BRAF gene in human cancer. Nature 2002, 417:949-954. 10.1038/nature00766, 12068308.
26. Konecny GE, Pegram MD, Venkatesan N, Finn R, Yang G, Rahmeh M, Untch M, Rusnak DW, Spehar G, Mullin RJ, Keith BR, Gilmer TM, Berger M, Podratz KC, Slamon DJ. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res 2006, 66:1630-1639. 10.1158/0008-5472.CAN-05-1182, 16452222.
27. Yost SE, Pastorino S, Rozenzhak S, Smith EN, Chao YS, Jiang P, Kesari S, Frazer KA, Harismendy O. High-resolution mutational profiling suggests the genetic validity of glioblastoma patient-derived pre-clinical models. PLoS One 2013, 8:e56185. 10.1371/journal.pone.0056185, 3575368, 23441165.
28. Shoemaker RH, Monks A, Alley MC, Scudiero DA, Fine DL, McLemore TL, Abbott BJ, Paull KD, Mayo JG, Boyd MR. Development of human tumor cell line panels for use in disease-oriented drug screening. Prog Clin Biol Res 1988, 276:265-286.
29. Weinstein JN, Myers TG, O'Connor PM, Friend SH, Fornace AJ, Kohn KW, Fojo T, Bates SE, Rubinstein LV, Anderson NL, Buolamwini JK, van Osdol WW, Monks AP, Scudiero DA, Sausville EA, Zaharevitz DW, Bunow B, Viswanadhan VN, Johnson GS, Wittes RE, Paull KD. An information-intensive approach to the molecular pharmacology of cancer. Science 1997, 275:343-349. 10.1126/science.275.5298.343, 8994024.
30. Sadanandam A, Lyssiotis CA, Homicsko K, Collisson EA, Gibb WJ, Wullschleger S, Ostos LC, Lannon WA, Grotzinger C, Del Rio M, Lhermitte B, Olshen AB, Wiedenmann B, Cantley LC, Gray JW, Hanahan D. A colorectal cancer classification system that associates cellular phenotype and responses to therapy. Nat Med 2013, 19:619-625. 10.1038/nm.3175, 3774607, 23584089.
31. Von Hoff DD, Stephenson JJ, Rosen P, Loesch DM, Borad MJ, Anthony S, Jameson G, Brown S, Cantafio N, Richards DA, Fitch TR, Wasserman E, Fernandez C, Green S, Sutherland W, Bittner M, Alarcon A, Mallery D, Penny R. Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers. J Clin Oncol 2010, 28:4877-4883. 10.1200/JCO.2009.26.5983, 20921468.
32. Rajendran P, Ong TH, Chen L, Li F, Shanmugam MK, Vali S, Abbasi T, Kapoor S, Sharma A, Kumar AP, Hui KM, Sethi G. Suppression of signal transducer and activator of transcription 3 activation by butein inhibits growth of human hepatocellular carcinoma in vivo. Clin Cancer Res 2011, 17:1425-1439. 10.1158/1078-0432.CCR-10-1123, 21131551.
33. Sultana Z, Paleologou KE, Al-Mansoori KM, Ardah MT, Singh N, Usmani S, Jiao H, Martin FL, Bharath MM, Vali S, El-Agnaf OM. Dynamic modeling of alpha-synuclein aggregation in dopaminergic neuronal system indicates points of neuroprotective intervention: experimental validation with implications for Parkinson's therapy. Neuroscience 2011, 199:303-317.